⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Elevated cost per beneficiary
Risk indicators are statistical patterns, not allegations. Learn more
4,258
Total Claims
$3.0M
Drug Cost
460
Beneficiaries
$6,418
Cost/Patient
Risk Score Breakdown 3/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+3
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+63%
Cost per patient vs peers
$6,418 vs $3,933 avg
+23%
Brand preference vs peers
62.7% vs 51.2% avg
Brand vs Generic
37% generic
Brand: 2,443 claims · $2.8M
Generic: 1,453 claims · $33K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 327 | $497K |
| Semaglutide | 156 | $248K |
| Insulin Degludec | 147 | $207K |
| Empagliflozin | 153 | $201K |
| Insulin Aspart | 115 | $166K |
| Finerenone | 121 | $147K |
| Dapagliflozin Propanediol | 93 | $127K |
| Tirzepatide | 93 | $120K |
| Insulin Glargine,hum.Rec.Anlog | 103 | $119K |
| Insulin Glargine,hum.Rec.Anlog | 121 | $107K |
| Semaglutide | 55 | $101K |
| Insulin Lispro | 69 | $98K |
| Insulin Aspart | 44 | $74K |
| Insulin Lispro | 51 | $71K |
| Insulin Regular, Human | 33 | $60K |
Prescribing Profile
Patient Profile
71
Avg Age
64%
Female
1.57
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About